Please select the eligibility criteria that correspond to the clinical trial below.
Title: Live Birth After Fresh Embryo Transfer vs Elective Embryo Cryopreservation/Frozen Embryo Transfer in Women With Polycystic Ovary Syndrome Undergoing IVF: A Multi-center Prospective Randomized Clinical Trial
Brief Summary: Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders in women of childbearing age. However, the optimal infertility treatment for PCOS patients is still a matter of controversy. Despite producing more follicles and more oocytes than other women undergoing controlled ovarian hyperstimulation during an IVF cycle, women with PCOS have comparable or lower pregnancy rates. Additionally women with PCOS patients undergoing IVF have a higher risk of developing ovarian hyperstimulation syndrome (OHSS), which may be aggravated by pregnancy after an embryo transfer in a fresh cycle. Further women with PCOS are thought to have higher rates of later pregnancy complications including spontaneous abortion, pre-eclampsia, and preterm labor that may be related to impaired implantation in the superovulated endometrium. We propose a randomized clinical trial of elective embryo cryopreservation followed by a programmed cycle of endometrial preparation and frozen embryo transfer (FET) compared to fresh embryo transfer in women with PCOS undergoing in vitro fertilization (IVF).


Options:
A: Inclusion Criteria:

* Women diagnosed as PCOS according to Chinese PCOS diagnosis criteria;
* Women who have ≥1 years history of infertility;
* Women aged ≥20 and \<35 years old;
* Women with body weight ≥40kg;
* Women who have at least one of the following indications for IVF or ICSI:

  1. Ovulation dysfunction and failed to become pregnant from ovulation induction treatment;
  2. Tubal factors: unilateral or bilateral tubal obstruction, adhesion, unilateral or bilateral Salpingectomy or tubal ligation;
  3. Male factors: oligoasthenozoospermia, obstructive azoospermia;
* Women who are undergoing their first cycle of IVF or ICSI;
* Women who retrieved oocytes number \> 3;
* Women who are capable of giving informed consent.

Exclusion Criteria:

* Women who underwent unilateral ovariectomy;
* Women diagnosed as uterus abnormality: malformed uterus (uterus unicorns, septate uterus, duplex uterus, uterus bicomis), adenomyosis, submucous myoma, intrauterine adhesion;
* Women or their partner with abnormal chromosome karyotype including chromosome polymorphism;
* Women who have experienced recurrent spontaneous abortion (including biochemical pregnancy abortion) more than 2 times;
* Women with medical condition that represent contraindication to assisted reproductive technology and/or pregnancy;
* Women who has developed severe OHSS before oocyte pick-up day;
* Women with retrieved oocytes number ≤3;
* Women who are unable to comply with the study procedures.
B: Inclusion Criteria:

* regular normo-ovulatory cycles (28 to 35 days)
* age \< 38 years,
* body mass index (BMI) between 18 and 30
* first or second IVF/ICSI attempt

Exclusion Criteria:

* high basal levels of serum FSH or E2,
* less than 5 follicles at the antral follicular count performed on day 3 of a spontaneous cycle,
* history of high (\>20 oocytes) or low (\< 5 oocytes) ovarian response in a previous IVF attempt
C: Inclusion Criteria:

* Patients less than 38 years of age.
* Healthy women starting their first IVF/ICSI cycle.
* No contraindication to Combined Oral Contraceptive (COC) use. Appendix 1
* Consent to randomization.

Exclusion Criteria:

* Any contraindication to COC use.
* Hypersensitivity to Nuva ring or any of its components.
* Language barrier to consent.
D: Inclusion Criteria:

* Females of couples with an indication for Controlled Ovarian Stimulation (COS) and in-vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI);
* \>=18 and \<=36 years of age at the time of signing informed consent;
* Body weight \> 60 and \<=90 kg and body mass index (BMI) \>=18 and \<=32 kg/m\^2;
* Normal menstrual cycle length: 24-35 days;
* Availability of ejaculatory sperm (use of donated and/or cryopreserved sperm is allowed);
* Willing and able to sign informed consent.

Exclusion Criteria:

* History of/or any current (treated) endocrine abnormality;
* History of ovarian hyper-response or ovarian hyperstimulation syndrome

(OHSS);

* History of/or current polycystic ovary syndrome (PCOS);
* More than 20 basal antral follicles \<11 mm (both ovaries combined) as measured on ultrasound scan (USS) in the early follicular phase (menstrual cycle day 2-5);
* Less than 2 ovaries or any other ovarian abnormality (including endometrioma \> 10 mm; visible on USS);
* Presence of unilateral or bilateral hydrosalphinx (visible on USS);
* Presence of any clinically relevant pathology affecting the uterine cavity or fibroids \>=5 cm;
* More than three unsuccessful IVF cycles since the last established ongoing pregnancy (if applicable);
* History of non- or low ovarian response to FSH/ human menopausal gonadotropin (hMG) treatment;
* History of recurrent miscarriage (3 or more, even when unexplained);
* FSH \> 12 IU/L or LH \> 12 IU/L as measured by the local laboratory (sample taken during the early follicular phase: menstrual cycle day 2-5);
* Any clinically relevant abnormal laboratory value based on a sample taken during the screening phase;
* Contraindications for the use of gonadotropins (e.g. tumors, pregnancy/lactation, undiagnosed vaginal bleeding, hypersensitivity, ovarian cysts);
* Recent history of/or current epilepsy, human immunodeficiency virus (HIV) infection, diabetes, cardiovascular, gastro-intestinal, hepatic, renal or pulmonary disease;
* Abnormal karyotyping of the patient or her partner (if karyotyping is performed);
* Smoking more than 5 cigarettes per day;
* History or presence of alcohol or drug abuse within 12 months prior to signing informed consent;
* Previous use of Org 36286;
* Use of hormonal preparations within 1 month prior to randomization;
* Hypersensitivity to any of the concomitant medication prescribed as part of the treatment regimen in this protocol;
* Administration of investigational drugs within three months prior to signing informed consent.

Answer: A